Lung Cancer Trials Ask AI to find trials
WithdrawnNot applicableNCT00581503
Official study title

Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer

Study summary

This study has been designed to utilize already obtained biopsy specimens for investigation of the utility of a new, non-invasive optical diagnostic technique. The study will allow a careful correlation between the Optical coherence tomography findings and conventional histology.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studieddiagnostic

The study team can explain what participation involves.

Who it may be forLung Cancer · Pleural Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 20, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Withdrawn

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?University of California, Irvine

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
University of California, Irvine
Interventions being studied
Device: diagnostic
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Adult 18 years and older
  • Having procedure of endobronchial, transbronchial, and / or pleural biopsy
Reasons someone may not be able to joinExclusion criteria
  • Currently participating in any other investigational drug or device evaluation.
  • Currently taking drugs that are sensitive to light.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Pulmonary and Critical Care Medicine, UCI Medical CenterOrange, California
  • Urology department, UCI Medical CenterOrange, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 20, 2022. Always confirm current availability with the study team.

View original record ↗